CA2389851A1 - Human igm antibodies to chemokine receptors - Google Patents
Human igm antibodies to chemokine receptors Download PDFInfo
- Publication number
- CA2389851A1 CA2389851A1 CA002389851A CA2389851A CA2389851A1 CA 2389851 A1 CA2389851 A1 CA 2389851A1 CA 002389851 A CA002389851 A CA 002389851A CA 2389851 A CA2389851 A CA 2389851A CA 2389851 A1 CA2389851 A1 CA 2389851A1
- Authority
- CA
- Canada
- Prior art keywords
- igm
- antibodies
- receptors
- cells
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000009410 Chemokine receptor Human genes 0.000 title claims description 38
- 108050000299 Chemokine receptor Proteins 0.000 title claims description 38
- 210000004027 cell Anatomy 0.000 claims abstract description 146
- 102000005962 receptors Human genes 0.000 claims abstract description 72
- 108020003175 receptors Proteins 0.000 claims abstract description 72
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 69
- 102000019034 Chemokines Human genes 0.000 claims abstract description 38
- 108010012236 Chemokines Proteins 0.000 claims abstract description 38
- 241000700605 Viruses Species 0.000 claims abstract description 34
- 230000001404 mediated effect Effects 0.000 claims abstract description 15
- 230000003612 virological effect Effects 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 50
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 39
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 37
- 230000000781 anti-lymphocytic effect Effects 0.000 claims description 32
- 210000004698 lymphocyte Anatomy 0.000 claims description 30
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 23
- 238000003556 assay Methods 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 210000000265 leukocyte Anatomy 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 238000000338 in vitro Methods 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 6
- 230000009385 viral infection Effects 0.000 claims description 6
- 238000012832 cell culture technique Methods 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 238000001727 in vivo Methods 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 239000003226 mitogen Substances 0.000 claims description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000008478 viral entry into host cell Effects 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 abstract description 51
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 23
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 20
- 206010061818 Disease progression Diseases 0.000 abstract description 8
- 230000005750 disease progression Effects 0.000 abstract description 8
- 108010061299 CXCR4 Receptors Proteins 0.000 abstract description 5
- 102000012000 CXCR4 Receptors Human genes 0.000 abstract description 5
- 230000007502 viral entry Effects 0.000 abstract description 5
- 102000004274 CCR5 Receptors Human genes 0.000 abstract 1
- 108010017088 CCR5 Receptors Proteins 0.000 abstract 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 46
- 108010055166 Chemokine CCL5 Proteins 0.000 description 46
- 230000005764 inhibitory process Effects 0.000 description 30
- 102000000588 Interleukin-2 Human genes 0.000 description 21
- 108010002350 Interleukin-2 Proteins 0.000 description 21
- 230000035605 chemotaxis Effects 0.000 description 20
- 108010052285 Membrane Proteins Proteins 0.000 description 17
- 101000614439 Homo sapiens Keratin, type I cytoskeletal 15 Proteins 0.000 description 14
- 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 description 14
- 208000031886 HIV Infections Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000000684 flow cytometry Methods 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 230000004907 flux Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241001529936 Murinae Species 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 101710125089 Bindin Proteins 0.000 description 3
- 102000001902 CC Chemokines Human genes 0.000 description 3
- 108010040471 CC Chemokines Proteins 0.000 description 3
- 108050006947 CXC Chemokine Proteins 0.000 description 3
- 102000019388 CXC chemokine Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 239000012506 Sephacryl® Substances 0.000 description 3
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 101100361281 Caenorhabditis elegans rpm-1 gene Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000004976 peripheral blood cell Anatomy 0.000 description 2
- -1 predominantly Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 108010008385 glycolipid receptor Proteins 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/439,690 | 1999-11-14 | ||
| US43969099A | 1999-11-15 | 1999-11-15 | |
| US09/684,813 | 2000-10-10 | ||
| US09/684,813 US6610834B1 (en) | 1998-11-18 | 2000-10-10 | Human IgM antibodies to chemokine receptors |
| PCT/US2000/031051 WO2001035980A1 (en) | 1999-11-14 | 2000-11-14 | HUMAN IgM ANTIBODIES TO CHEMOKINE RECEPTORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2389851A1 true CA2389851A1 (en) | 2001-05-25 |
Family
ID=27032133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002389851A Abandoned CA2389851A1 (en) | 1999-11-14 | 2000-11-14 | Human igm antibodies to chemokine receptors |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6610834B1 (enExample) |
| EP (1) | EP1231930B1 (enExample) |
| JP (1) | JP2003516940A (enExample) |
| AT (1) | ATE464909T1 (enExample) |
| AU (1) | AU1599601A (enExample) |
| CA (1) | CA2389851A1 (enExample) |
| DE (1) | DE60044259D1 (enExample) |
| WO (1) | WO2001035980A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030099645A1 (en) * | 2000-10-10 | 2003-05-29 | Lobo Peter Isaac | Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes |
| US20080118522A1 (en) * | 1998-11-18 | 2008-05-22 | Lobo Peter I | Naturally occuring IgM antibodies that bind lymphocytes |
| WO2005108989A2 (en) * | 2004-04-16 | 2005-11-17 | Genentech, Inc. | Assay for antibodies |
| EP1817054A1 (en) * | 2004-12-01 | 2007-08-15 | Peter I. Lobo | Naturally occuring igm antibodies that bind lymphocytes |
| TW200720289A (en) | 2005-04-01 | 2007-06-01 | Hoffmann La Roche | Antibodies against CCR5 and uses thereof |
| BRPI0707446A2 (pt) | 2006-02-02 | 2011-05-03 | Allergan Inc | composições e métodos para o tratamento de doença oftálmica |
| TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
| WO2008019817A1 (en) | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
| KR20090052358A (ko) | 2006-09-29 | 2009-05-25 | 에프. 호프만-라 로슈 아게 | Ｃｃｒ5 에 대한 항체 및 이의 용도 |
| CL2008000707A1 (es) * | 2007-03-13 | 2008-09-22 | Hoffmann La Roche | Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion. |
| GB201002238D0 (en) | 2010-02-10 | 2010-03-31 | Affitech As | Antibodies |
| EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US20210311048A1 (en) * | 2016-02-16 | 2021-10-07 | Celltrend Gmbh | Anti-CXC chemokine receptor antibodies and C-X-C chemokines for the diagnosis of autoimmune disease and graft-versus-host disease |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8605316D0 (en) * | 1986-03-04 | 1986-04-09 | Royal Free Hosp School Med | Immunosuppression |
| US5215913A (en) * | 1987-11-30 | 1993-06-01 | Roger Williams General Hospital | IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use |
| US5606026A (en) * | 1988-03-25 | 1997-02-25 | The Institute For Human Genetics And Biochemistry | Natural human IgM antibodies immunoreactive with the Tat protein of HIV-1 |
| EP0672142B1 (en) * | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| US5961976A (en) * | 1996-06-03 | 1999-10-05 | United Biomedical, Inc. | Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV |
| WO1997049424A1 (en) * | 1996-06-25 | 1997-12-31 | The Trustees Of The University Of Pennsylvania | Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
| US5994515A (en) * | 1996-06-25 | 1999-11-30 | Trustees Of The University Of Pennsylvania | Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
| US6057102A (en) * | 1996-08-08 | 2000-05-02 | The Aaron Diamond Aids Research Center | HIV coreceptor mutants |
| US6100387A (en) | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
| JP2000229997A (ja) * | 1999-02-10 | 2000-08-22 | Nissui Pharm Co Ltd | 環状ペプチド及びエイズワクチン |
-
2000
- 2000-10-10 US US09/684,813 patent/US6610834B1/en not_active Expired - Fee Related
- 2000-11-14 AT AT00978542T patent/ATE464909T1/de not_active IP Right Cessation
- 2000-11-14 AU AU15996/01A patent/AU1599601A/en not_active Abandoned
- 2000-11-14 DE DE60044259T patent/DE60044259D1/de not_active Expired - Lifetime
- 2000-11-14 CA CA002389851A patent/CA2389851A1/en not_active Abandoned
- 2000-11-14 EP EP00978542A patent/EP1231930B1/en not_active Expired - Lifetime
- 2000-11-14 WO PCT/US2000/031051 patent/WO2001035980A1/en not_active Ceased
- 2000-11-14 JP JP2001537971A patent/JP2003516940A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1231930A4 (en) | 2005-07-27 |
| JP2003516940A (ja) | 2003-05-20 |
| ATE464909T1 (de) | 2010-05-15 |
| EP1231930A1 (en) | 2002-08-21 |
| AU1599601A (en) | 2001-05-30 |
| US6610834B1 (en) | 2003-08-26 |
| EP1231930B1 (en) | 2010-04-21 |
| DE60044259D1 (de) | 2010-06-02 |
| WO2001035980A1 (en) | 2001-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Elsner et al. | Differential activation of CC chemokine receptors by AOP-RANTES | |
| AU724037B2 (en) | Antibodies binding to monocyte chemoattractant protein 1 (MCP-1) receptor (CCR2) | |
| Jelcic et al. | Broadly neutralizing human monoclonal JC polyomavirus VP1–specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy | |
| Chen et al. | Shikonin, a component of Chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1 | |
| JP4148537B2 (ja) | Ｃｄ４０ｃｒレセプター及びそれに対するリガンド | |
| US6610834B1 (en) | Human IgM antibodies to chemokine receptors | |
| CN102988959B (zh) | Nkg2d的调节 | |
| EP3087100A1 (en) | Therapeutic methods and compositions | |
| Pollara et al. | Redirection of cord blood T cells and natural killer cells for elimination of autologous HIV-1-infected target cells using bispecific DART® molecules | |
| US20050220787A1 (en) | Naturally occuring IgM antibodies that bind to lymphocytes | |
| US20030099645A1 (en) | Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes | |
| Lobo et al. | Naturally occurring IgM anti-leukocyte autoantibodies (IgM-ALA) inhibit T cell activation and chemotaxis | |
| AU766882B2 (en) | Product and method for treatment of conditions associated with receptor-desensitization | |
| van Delft et al. | Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity | |
| Warren et al. | Convergence between CD98 and integrin‐mediated T‐lymphocyte co‐stimulation | |
| Silvestris et al. | Cross-linking of Fas By Antibodies to a Peculiar Domain of gp120 V3 Loop Can Enhance T Cell Apoptosis in HIV-1–infected Patients | |
| Sindre et al. | Human intestinal endothelium shows high susceptibility to cytomegalovirus and altered expression of adhesion molecules after infection | |
| Gurevich‐Shapiro et al. | Intravenous immunoglobulin–induced acute thrombocytopenia | |
| US20080118522A1 (en) | Naturally occuring IgM antibodies that bind lymphocytes | |
| Elenström-Magnusson et al. | IL-4-induced B cell migration involves transient interactions between β1 integrins and extracellular matrix components | |
| JP2007505141A (ja) | Ｃｄ９９アンタゴニストを用いる慢性関節リウマチの処置 | |
| JP2019507102A (ja) | 抗−ヒトｉｌ−３抗体、ｉｌ−３の高められた発現又はレベルに関連する疾患又は機能障害へのそれらの使用、及びヒトｉｌ−３の検出方法へのそれらの使用 | |
| US20080112950A1 (en) | Naturally occurring IgM antibodies that bind lymphocytes | |
| Tanaka et al. | Suppression of CCR5-tropic HIV type 1 infection by OX40 stimulation via enhanced production of β-chemokines | |
| WO2006059176A1 (en) | Naturally occuring igm antibodies that bind lymphocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |